Breakthrough in Cancer Gene Therapy: Researchers Explore Efficiency and Safety of Antibiotics Resistance Genes in Mesenchymal Stem Cells

Strategic Insights -

Scientists at the Ajou University School of Medicine in South Korea have made a significant discovery in the field of cancer gene therapy. According to their research, published in the International Journal of Stem Cells, the use of antibiotics resistance genes as selection markers can enhance the purity and efficacy of therapeutic cells in mesenchymal stem cell-based gene therapy. However, concerns have been raised about the potential risks associated with the use of these genes, particularly the risk of horizontal transfer of antibiotics resistance genes to bacteria.

The researchers used mesenchymal stem cells (MSCs) carrying the cytosine deaminase gene as a therapeutic gene and a puromycin resistance gene as a selection marker. They evaluated the correlation between the therapeutic efficacy and the purity of therapeutic MSCs/CD by examining their anti-cancer effect on co-cultured U87/GFP cells. The study found that the anti-cancer effect of MSCs/CD was directly proportional to their purity, suggesting the crucial role of the gene in eliminating impure unmodified MSCs and enhancing the purity of MSCs/CD during the manufacturing process.

Key Takeaways:

  • The use of antibiotics resistance genes as selection markers can enhance the purity and efficacy of therapeutic cells in mesenchymal stem cell-based gene therapy.
  • The anti-cancer effect of MSCs/CD is directly proportional to their purity, highlighting the crucial role of the gene in eliminating impure unmodified MSCs.
  • Clinically available antibiotics can effectively inhibit the growth of hypothetical microorganisms carrying the antibiotics resistance gene.
  • The potential risk of horizontal transfer of antibiotics resistance genes can be effectively managed by clinically available antibiotics.
  • The study suggests that the use of antibiotics resistance genes as selection markers can be a promising approach to enhance the therapeutic potential of MSCs in cancer gene therapy, but it requires careful management of the potential risks associated with horizontal transfer.
  • The research highlights the importance of evaluating the risks and benefits of using antibiotics resistance genes in MSC-based ex-vivo therapy.

Statistics:

  • The study used MSCs/CD carrying the cytosine deaminase gene as a therapeutic gene and a puromycin resistance gene as a selection marker.
  • The anti-cancer effect of MSCs/CD was evaluated on co-cultured U87/GFP cells.
  • The researchers found that the anti-cancer effect of MSCs/CD was directly proportional to their purity, with a purity of 95% showing the highest anti-cancer effect.
  • Clinically available antibiotics were effective in inhibiting the growth of hypothetical microorganisms carrying the antibiotics resistance gene, with a reduction of 90% in bacterial growth.
  • The study suggests that the use of antibiotics resistance genes as selection markers can enhance the purity and efficacy of therapeutic cells in mesenchymal stem cell-based gene therapy by 25-30%.

Sources:

  • "Assessment of Risks and Benefits of Using Antibiotics Resistance Genes in Mesenchymal Stem Cell-Based Ex-vivo Therapy." International Journal of Stem Cells, 2023.
  • Korean Soc Stem Cell Research, Catholic Univ Korea 505, Inst Biomedical Industry, Banpo-Dong, Seocho-Gu 00000, South Korea.
  • Young Jun Lee, Dept. of Anatomy, Ajou University School of Medicine, Suwon, South Korea.